These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20831779)

  • 1. Partial third nerve palsy after Measles Mumps Rubella vaccination.
    Manzotti F; Menozzi C; Porta MR; Orsoni JG
    Ital J Pediatr; 2010 Sep; 36():59. PubMed ID: 20831779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, reactogenicity and immunogenicity of the live attenuated combined measles, mumps and rubella vaccine containing the RIT 4385 mumps strain in healthy Singaporean children.
    Lim FS; Han HH; Bock HL
    Ann Acad Med Singap; 2007 Dec; 36(12):969-73. PubMed ID: 18185875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Events Among Young Adults Following a Third Dose of Measles-Mumps-Rubella Vaccine.
    Marin M; Fiebelkorn AP; Bi D; Coleman LA; Routh J; Curns AT; McLean HQ
    Clin Infect Dis; 2021 Oct; 73(7):e1546-e1553. PubMed ID: 32766827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
    Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
    Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of measles, rubella and mumps vaccines in adults: a prospective cohort study.
    Ami N; Eyal N; Asaf B; Chen A; Adi B; Drorit A; Neta P; Hajar D; Stav R; Eli S
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34101817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up.
    Patja A; Davidkin I; Kurki T; Kallio MJ; Valle M; Peltola H
    Pediatr Infect Dis J; 2000 Dec; 19(12):1127-34. PubMed ID: 11144371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunogenicity and safety of a boost dose of measles, mumps, and rubella combined vaccine for 4-6 years old children].
    Xiao YH; Chang SY; Bai S; Zhao RM; Wang JH; Wang XQ; Yang YK; Ma YL; Liu XQ; Luo LY; Lyu M; Chen HP
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Jun; 42(6):1086-1091. PubMed ID: 34814512
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse reactions in estimation of MMR vaccination validation in Bosnian population.
    Trninic S; Bajraktarevic A
    Med Arh; 2009; 63(4):228-30. PubMed ID: 20088182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
    Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K; Goa KL
    Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial.
    Bavdekar A; Oswal J; Ramanan PV; Aundhkar C; Venugopal P; Kapse D; Miller T; McGray S; Zehrung D; Kulkarni PS;
    Vaccine; 2018 Feb; 36(9):1220-1226. PubMed ID: 29395526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulomatous dermatitis following measles, mumps, and rubella vaccination.
    Samaran Q; Clark E; Secco LP; Poujade L; Schwob E; Bessis D; Raison-Peyron N
    Pediatr Dermatol; 2021 Sep; 38(5):1382-1384. PubMed ID: 34263490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial.
    Platt H; Tochihara S; Oda Y; Ueda K
    Jpn J Infect Dis; 2021 Sep; 74(5):429-436. PubMed ID: 33518626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.